ZNTL Zentalis Pharmaceuticals, Inc.

NASDAQ
$2.70

Zentalis Pharmaceuticals, Inc. (ZNTL) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.58 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -42.3% since its last earnings release on August 6, 2026.

Zentalis Pharmaceuticals Missed Consensus Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.58)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.64

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.